How many patients and blood levels are necessary for population pharmacokinetic analysis? A study of a one compartment model applied to cyclosporine

European Journal of Clinical Pharmacology

Volumn 51, Issue 3-4, 1996, Pages 283-288

  Breant V ^a   Charpiat, B ^a   Sab, J M ^a   Maire, P ^b   Jelliffe, R W ^c  

^a CROIX ROUSSE HOSPITAL   (France)

^b A Charial Hospital   (France)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

cyclosporine; experimental design; population pharmacokinetic analysis; population size; sample number

Indexed keywords

CYCLOSPORIN A;

ADULT; ALGORITHM; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; FEMALE; HUMAN; LIVER TRANSPLANTATION; MALE; PHARMACOKINETICS; POPULATION; PRIORITY JOURNAL;

CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RESEARCH DESIGN; SAMPLE SIZE;

EID: 0030445376     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050199     Document Type: Article

References (27)

1. Aarons L, Balant LP, Mentré F, Morselli PL, Rowland M, Steimer JL, Vozeh S (1994) Cost 1B "Expert meeting and population software Brussels. Population approches in drug development: report on expert meeting to discuss population pharmacokinetic/pharmacodynamic software." Eur J Clin Pharmacol 46:389-391
2. Sheiner LB, Beal LS (1981) Some suggestions for measuring predictive performances. J Pharmacokinet Biopharm 9:503-512
3. Jelliffe RW, Iglesias T, Hurst AK, Foo KA, Rodriguez J (1991) Individualising gentamicin dosage regimens. A comparative review of selected models, data fitting methods and monitoring strategies. Clin Pharmacokinet 21:461-478
4. Kato Z, Fukutomi O, Yamazaki M, Kondo N, Imaeda N, Orii T (1994) Prediction of steady-state serum theophylline concentration in children by first-order and zero order absorption models. Int J Clin Pharmacol Ther Toxicol 5:231-234
5. Modi BN, Veng-Pedersen P, Graham DJ, Dow RJ (1993) Application of a system analysis approach to population pharmacokinetics and pharmacodynamics of nicardipine hydrochloride in healthy males. J Pharm Sci 82:705-713
6. Charpiat B, Breant V, Pivot-Dumarest C, Maire P, Jelliffe RW (1994) Prediction of future serum concentrations with Bayesian fitted models: results with data collected by nurses versus trained pharmacy residents. Ther Drug Monit 16:166-173
7. Anderson JE, Munday AS, Kelman AW, Briggs JD, Knepil J, Thompson AH (1994) Evaluation of a bayesian approach to the pharmacokinetic interpretation of cyclosporin concentrations in renal allograft recipients. Ther Drug Monit 16:160-165
8. Ette EI, Kelman AW, Howie CA, Whiting B (1993) Interpretation of simulation studies for efficient estimation of population pharmacokinetic parameters. Ann Pharmacother 27:1034-1039
9. Taright N, Mentré F, Mallet A, Jouvent R (1994) Nonparametric estimation population characteristics of the kinetics of lithium from observational and experimental data: individualization of chronic dosing regimen using a new Bayesian approach. Ther Drug Monit 16:258-269
10. Iliadis A, Brown AC, Huggins ML (1992) APIS: a software for model identification, simulation and dosage regimen calculations in clinical and experimental pharmacokinetics. Comput Meth Prog Biomed 38:227-239
11. Al-Banna MK, Kelman AW, Whiting B (1990) Experimental design and efficient parameter estimation in population pharmacokinetics. J Pharmacokinet Biopharm 18:347-360
12. Whiting B (1992) The population approach: applications to date. An overview. In: Rowland M, Aarons L (eds) New strategies in drug development and clinical evaluation. The population approach. Commission of the European Communities, Luxembourg, pp 41-56
13. Vozeh S (1992) Applications of population approach to clinical pharmacokinetics and validation of the results. In: Rowland M, Aarons L (eds) New strategies in drug development and clinical evaluation. The population approach. Commission of the European Communities, Luxembourg, pp 107-120
14. Steimer JL (1992) Population models and methods, with emphasis on pharmacokinetics. In: Rowland M, Aarons L (eds) New strategies in drug development and clinical evaluation. The population approach. Commission of the European Communities, Luxembourg, pp 31-40
15. Aarons L, Balant LP, Mentré F, Morselli PL, Rowland M, Steimer JL, Vozeh S (1996) Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies. Eur J Clin Pharmacol 49:251-254
16. Schumitzky A (1991) Nonparametric EM algorithms for estimating prior distributions. Appl Math Comput 45:143-151
17. Gupta SK, Bakran A, Johnson RWG, Rowland M (1989) Pharmacokinetics of cyclosporin: influence of rate duration profile of an intravenous infusion in renal transplant patients. Br J Clin Pharmacol 27:353-357
18. Turgeon KD, Normolle DP, Leichtman AB, Annesley TM, Smith DE, Watkins PB (1992) Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients. Clin Pharmacol Ther 52:471-478
19. Lindholm A, Kahan BD (1993) Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 54:205-218
20. Burckart G, Starzl T, Sanghvi A, Gartner C, Venkataramanan JB, Zitelli B, Malatack J, Urbach A, Diven W, Ptachinsky R, Shaw B, Iwatsuki S (1985) Cyclosporine monitoring and pharmacokinetics in pediatric liver transplant patients. Transplant Proc 17:1172-1175
21. Whitington F, Edmond JC, Whitington SH, Broelsch C, Baker AL (1990) Small-bowel length and the dose of cyclosporine in children after liver transplantation. N Engl J Med 322:733-738
22. Tredger JM, Grevel J, Naoumov N, Steward CM, Niven AA, Whiting B, Williams R (1991) Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis. Eur J Clin Pharmacol 40:513-519
23. Weber W, Looby M, Brockmöller J (1992) Evaluation of hepatic function using the pharmacokinetics of therapeutically administered drug: application to the immunosuppressant cyclosporin. Clin Pharmacokinet 23:69-83
24. Klompmaker IJ, Wierda JMKH, Sluiter WJ, Uges DRA, Haagsma EB, Verwer R, Slooff MJH (1993) Pharmacokinetics of cyclosporine A after intravenous and oral administration in liver transplant patients measured with high-performance liquid chromatography. Ther Drug Monit 15:60-64
25. Tan KKC, Trull AK, Hue KL, Best NG, Wallwork J, Higenbottam TW (1993) Pharmacokinetics of cyclosporine in heart and lung transplant candidates and recipients with cystic fibrosis and Eisenmenger's syndrome. Clin Pharmacol Ther 53:544-554
26. Tsang VT, Johnston A, Leaver N, Hodson ME, Yacoub M (1994) Cyclosporine pharmacokineties in heart-lung transplant recipients with cystic fibrosis. Effects of pancreatic enzymes and ranitidine. Eur J Clin Pharmacol 46:261-265
27. Whiting B, Niven AA, Kelman AW, Thomson AH, Anderson JE, Munday A, Briggs JD (1991) A Bayesian kinetic control strategy for cyclosporin in renal transplantation. In: D'Argenio DZ (ed) Advance methods in pharmacokinetic and pharmacodynamic systems analysis. Plenum Press, New York, pp 171-176